Aerie's Rhopressa wins FDA panel votes

An FDA advisory committee voted 9-1 on Oct. 13 that the efficacy of Rhopressa netarsudil 0.02% (AR-13324) from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shown in

Read the full 242 word article

How to gain access

Continue reading with a
two-week free trial.